MedTrace Logo

Biomarkers of Synaptic Damage in Multiple Sclerosis

NCT03217396 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2022-10-28

No results posted yet for this study

Summary

A prospective and retrospective cohort study of about five years will be performed on blood and cerebrospinal fluid samples taken for diagnostic reasons from recruited patients within the Neuromed Neurology Unit. Subjects with other chronic neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD) and Parkinson's disease (PD), and healthy subjects subjected to blood sampling and / or lumbar puncture for clinical reasons will be recruited As control groups.

Conditions

Interventions

PROCEDURE

lumbar puncture

lumbar puncture performed to detect OCB for diagnostic purposes

Sponsors & Collaborators

  • IRCCS Multimedica

    collaborator OTHER

  • Neuromed IRCCS

    lead OTHER

Principal Investigators

  • Diego Centonze, MD · IRCCS Neuromed

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-22
Primary Completion
2026-09-01
Completion
2027-09-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03217396 on ClinicalTrials.gov